Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth

[1]  P. Dahm,et al.  Circulating and tumor‐infiltrating myeloid cell subsets in patients with bladder cancer , 2012, International journal of cancer.

[2]  Jonathan B. Mitchem,et al.  Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. , 2011, Current cancer drug targets.

[3]  A. Epstein,et al.  Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines , 2011, Journal of Translational Medicine.

[4]  R. Aft.  Bisphosphonates in breast cancer: antitumor effects. , 2011, Clinical advances in hematology & oncology : H&O.

[5]  T. Ratliff,et al.  In vivo suppressive function of myeloid‐derived suppressor cells is limited to the inflammatory site , 2011, European journal of immunology.

[6]  D. Link,et al.  Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice , 2011 .

[7]  P. Zabel,et al.  Myeloid‐derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties , 2011, Journal of leukocyte biology.

[8]  D. Link,et al.  Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization , 2011, Leukemia.

[9]  V. Bronte,et al.  Myeloid cell diversification and complexity: an old concept with new turns in oncology , 2011, Cancer and Metastasis Reviews.

[10]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[11]  A. Epstein,et al.  Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells , 2010, The Journal of Immunology.

[12]  D. Link,et al.  CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. , 2010, The Journal of clinical investigation.

[13]  S. Bicciato,et al.  Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. , 2010, Immunity.

[14]  C. Jackson-Cook,et al.  Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma+vaccination model , 2010, Journal of Neuroimmunology.

[15]  A. Dietz,et al.  Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. , 2010, Neuro-oncology.

[16]  V. Bronte,et al.  Myeloid-derived suppressor cell heterogeneity and subset definition. , 2010, Current opinion in immunology.

[17]  E. Celis,et al.  Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells , 2010, The Journal of Immunology.

[18]  M. Sporn,et al.  Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer , 2010, Clinical Cancer Research.

[19]  K. Pienta,et al.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. , 2010, Cytokine & growth factor reviews.

[20]  E. Traggiai,et al.  Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSF , 2009, European journal of immunology.

[21]  P. Musiani,et al.  Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway , 2009, Journal of cellular and molecular medicine.

[22]  P. Sinha,et al.  Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. , 2010, Cancer research.

[23]  M. Manns,et al.  Increase in frequency of myeloid‐derived suppressor cells in mice with spontaneous pancreatic carcinoma , 2009, Immunology.

[24]  P. Sinha,et al.  Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells1 , 2009, The Journal of Immunology.

[25]  P. Dong,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[26]  T. Padhya,et al.  Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells1 , 2009, The Journal of Immunology.

[27]  B. Rini,et al.  Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[28]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[29]  M. Atkins,et al.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.

[30]  T. Eberlein,et al.  Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer1 , 2009, The Journal of Immunology.

[31]  Xuetao Cao,et al.  Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11 , 2009, The Journal of Immunology.

[32]  P. Sinha,et al.  Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4 and CD8 T Cells , 2009 .

[33]  Fu-Tsai Chung,et al.  Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer , 2009, Journal of Cancer Research and Clinical Oncology.

[34]  P. Dahm,et al.  Reversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma , 2008, Clinical Cancer Research.

[35]  Michelle Collazo,et al.  Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.

[36]  A. Schweitzer,et al.  Biodistribution and Plasma Protein Binding of Zoledronic Acid , 2008, Drug Metabolism and Disposition.

[37]  K. Trinkaus,et al.  Adjuvant Interferon-based Chemoradiation Followed By Gemcitabine for Resected Pancreatic Adenocarcinoma: A Single-Institution Phase II Study , 2008, Annals of surgery.

[38]  P. Dahm,et al.  Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma1 , 2008, The Journal of Immunology.

[39]  V. Bronte,et al.  Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.

[40]  P. De Baetselier,et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.

[41]  D. Kranz,et al.  Equilibrium between host and cancer caused by effector T cells killing tumor stroma. , 2008, Cancer research.

[42]  P. Pisa,et al.  Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages , 2008, Cancer Immunology, Immunotherapy.

[43]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[44]  C. Divino,et al.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. , 2008, Blood.

[45]  Z. Werb,et al.  Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.

[46]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[47]  M. Caraglia,et al.  Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.

[48]  W. Gong,et al.  CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. , 2007, Cancer letters.

[49]  L. Mariani,et al.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Büchler,et al.  Zoledronic Acid has Direct Antiproliferative and Antimetastatic Effect on Pancreatic Carcinoma Cells and Acts as an Antigen for δ2 γ/δ T Cells , 2007, Journal of immunotherapy.

[52]  T. Eberlein,et al.  Depletion of CD4+CD25+ Regulatory T Cells Promotes a Tumor-Specific Immune Response in Pancreas Cancer–Bearing Mice , 2006, Annals of Surgical Oncology.

[53]  T. Eberlein,et al.  Increased Prevalence of Regulatory T Cells (Treg) is Induced by Pancreas Adenocarcinoma , 2006, Journal of immunotherapy.

[54]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[55]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[56]  H. Tilg,et al.  The effect of zoledronic acid on the function and differentiation of myeloid cells. , 2006, Haematologica.

[57]  P. Sinha,et al.  Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. , 2005, Cancer research.

[58]  S. Dubinett,et al.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma , 2005, The Journal of experimental medicine.

[59]  D. Linehan,et al.  CD25+CD4+ regulatory T-cells in cancer , 2005, Immunologic research.

[60]  S. Di Cosimo,et al.  Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients , 2005, Oncology.

[61]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[62]  P. Sinha,et al.  Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.

[63]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[64]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[65]  S. Cingarlini,et al.  Derangement of immune responses by myeloid suppressor cells , 2004, Cancer Immunology, Immunotherapy.

[66]  G. Avvisati,et al.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  C. Boland,et al.  Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro , 2003, British Journal of Cancer.

[68]  L. Traverso,et al.  Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. , 2003, American journal of surgery.

[69]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[70]  A. Visintin,et al.  Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.

[71]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[72]  O. Finn,et al.  Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[74]  G. Bastert,et al.  Bisphosphonates and the prevention of metastasis , 2000, Cancer.

[75]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  F. Schabel,et al.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. , 1984, Cancer research.